Eight practices decided not to sell
On July 9, 2026, eight community-based oncology providers across five states announced that they were banding together rather than selling to private equity or a hospital system. The group, called the Anoma Cancer Collective, was organized by the consulting firm Radiation Business Solutions to give small practices shared access to capital, tax-exempt financing, bond-market funding, shared infrastructure and operational expertise — the resources that used to require handing over ownership.
The framing was explicit. "We believe community cancer care is worth fighting for," the group said in its announcement. "Physicians should not have to surrender their independence to survive, and families deserve care close to home…" Radiation Business Solutions said it had invested more than $10 million over 18 months in time, resources, and legal and financial structuring, and has placed over $300 million in bonds with radiation centers to date; its investors have now commissioned it to grow the collective by 60%.
Radiology sits under the same pressure that produced the Anoma Cancer Collective. The relevant question for an independent imaging group isn't whether consolidation is coming — the data says it already arrived — but what the alternatives actually are.
Private equity is already deep in radiology
A 2025 national analysis in the American Journal of Roentgenology quantified the trend: from 2013 to 2023, private equity firms acquired 151 radiology practices nationally, involving 3,463 practice locations, leaving roughly 12% of all US radiologists PE-employed.
The national average understates the local reality. Concentration clusters by state: in 2023, 47% of radiologists in Nevada and 44% in Arizona were employed by private-equity-backed platforms. In those markets, an "independent group" is already the exception, not the default.
The oncology data explains why physicians are wary of the trade. A 2026 study in the International Journal of Radiation Oncology, Biology, Physics tracked 423 oncology practices acquired by 82 PE firms between 2013 and 2022 — a 27% compound annual growth rate in deal volume. After acquisition, those practices showed 5.3% higher office-visit prices and a 50.1% increase in radiation-therapy spending versus non-PE peers. Consolidation changed the economics of care, not just the cap table.
Why groups sell: capacity and margin, not desire
Very few radiologists want to sell equity. They do it because the operating math gets hard: rising study volumes, a tight labor market for subspecialty readers, expensive after-hours and weekend coverage, and reimbursement that keeps drifting down. A PE platform or hospital offers scale — more readers, shared night coverage, back-office leverage — in exchange for ownership.
The Anoma Cancer Collective attacks that trade structurally: pool capital and infrastructure across practices so no single group has to sell to get scale. There is a second, complementary lever that is specific to imaging — attacking the capacity and margin problem operationally, so the reasons to sell shrink in the first place.
Two responses to the same pressure
Selling is not the only way to get scale. The structural and operational routes solve different parts of the same equation, and they stack.
| Lever | Sell to PE / hospital | Structural pact (e.g. Anoma) | Operational (AI reporting) |
|---|---|---|---|
| Ownership | Surrendered | Retained | Retained |
| Adds read capacity | Yes (via hiring) | Indirect | Yes (per-study throughput) |
| After-hours coverage | Shared pool | Shared pool | Draft-ahead triage |
| Upfront cost | Equity + control | Financing/legal setup | Per-study, no equity |
| Radiologist accountability | Employed model | Preserved | Your radiologist signs |
AI CT reporting as a capacity-and-margin lever
If the reasons a group sells are read volume, coverage and margin, then anything that adds capacity without adding equity dilution changes the calculus. AI-assisted CT reporting is that kind of lever. A foundation-model system reads the study and produces a structured, comprehensive draft; the human workflow then does what it always did, only faster.
Three practical effects matter for an independent group:
More reads per radiologist, without more hires
A ready-to-sign draft compresses the time from image to report. That lets a small group absorb volume growth it would otherwise need new headcount — or an acquirer — to handle.
After-hours coverage without a night pool
AI can triage and pre-draft overnight and weekend studies so the reading radiologist opens a structured preliminary instead of a cold worklist — coverage economics that used to require joining a larger platform.
Margin that stays in the practice
Per-study AI costs scale with volume and require no equity. Compare that to the PE oncology data, where acquisition was associated with a 50.1% rise in radiation-therapy spending — margin captured by the acquirer, not the practice.
The model keeps ownership — and accountability — with the group
The point of the Anoma Cancer Collective was that physicians should not have to trade the doctor-patient relationship for stability. An operational lever should honor the same principle. In AI CT reporting, the AI produces a draft, not a verdict — xAID's in-house radiologist reviews every preliminary, and the final signature stays with your reading radiologist. The group keeps its equity, its patients and its name on the report. Capacity goes up; ownership does not change hands. That is the case for treating consolidation as one option among several, not an inevitability.
Frequently asked questions
Is private equity really consolidating radiology?
Yes. A 2025 analysis in the American Journal of Roentgenology found that private equity firms acquired 151 radiology practices nationally from 2013 to 2023, involving 3,463 practice locations, leaving roughly 12% of all US radiologists PE-employed. Concentration is highly regional — in 2023, 47% of radiologists in Nevada and 44% in Arizona were PE-employed.
What is the Anoma Cancer Collective?
The Anoma Cancer Collective is a network of eight community-based oncology providers across five states, organized in July 2026 by consulting firm Radiation Business Solutions. Instead of selling to private equity or a hospital system, the practices banded together into a nonprofit structure that gives them shared access to tax-exempt financing, bond-market funding, shared infrastructure and operational expertise — a bid to preserve independence while adapting to reimbursement and cost pressure.
Can an independent radiology group grow without selling equity?
Yes. Groups facing consolidation pressure have two broad options: structural (nonprofit or cooperative networks like the Anoma Cancer Collective that pool capital and infrastructure) and operational (using technology to add read capacity and after-hours coverage without new hires or an equity sale). AI-assisted CT reporting is an operational lever — the AI produces a structured, ready-to-sign draft, xAID's in-house radiologist reviews every preliminary, and the final signature stays with your reading radiologist.
Does AI reduce the pressure to consolidate radiology practices?
It targets the underlying math that pushes groups to sell: capacity and margin. Research in the International Journal of Radiation Oncology, Biology, Physics found that PE-acquired oncology practices raised radiation-therapy spending by 50.1% and office-visit prices by 5.3% after acquisition. AI-assisted reporting aims to lift throughput and extend coverage without those price dynamics or a loss of ownership, while keeping a radiologist accountable for every final read.
Source: "Radiation oncology providers form nonprofit network in bid to preserve independence," Radiology Business (July 9, 2026); Khunte & Singh, "Private Equity Acquisitions of Radiology Practices From 2013 to 2023," AJR (2025); Abdelhadi & Arnold, "Private Equity Acquisitions in Oncology: Impact on Market Share and Prices," Int J Radiat Oncol Biol Phys (2026). Figures are rounded as reported.